Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Discovery Laboratories has completed its registered direct offering of 10 million shares of its common stock. The shares were issued and sold to a select group of institutional investors at a price of $2.50 per share resulting in gross proceeds of $25 million.
Subscribe to our email newsletter
All of the shares of common stock were offered and sold by Discovery Labs pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.
Discovery Laboratories is a biotechnology company developing surfactant replacement therapies (SRT) for respiratory diseases. Discovery Labs’ technology produces a precision-engineered surfactant that is designed to closely mimic the essential properties of natural human lung surfactant.